NT-proANP - a Biomarker for Cardiac Risk

The BIOMEDICA cardiac biomarker kits NT-proBNP and NT-proANP were used in a recent study exploring the potential for increased cardiovascular complications due to radioactive iodine treatment (RAI) effects in patients with differentiated thyroid cancer (DTC) with or without type 2 diabetes.

The Interplay Between High Cumulative Doses of Radioactive Iodine and Type 2 Diabetes Mellitus: A Complex Cardiovascular Challenge. Stanciu AE et al., Int J Mol Sci. 2024; 26(1):37. PMC11720250.

Abstract

Starting from the metabolic profile of type 2 diabetes mellitus (T2DM), we hypothesized that the mechanisms of ¹³¹I-induced cardiotoxicity differ between patients diagnosed with differentiated thyroid cancer (DTC) with/without T2DM, with metformin potentially acting as a cardioprotective agent by mitigating inflammation in patients with T2DM. To address this hypothesis, we quantified, using ELISA, the serum concentration of several key biomarkers that reflect cardiac injury (NT-proBNP, NT-proANP, ST2/IL-33R, and cTn I) in 74 female patients with DTC/-T2DM and 25 with DTC/+T2DM treated with metformin. All patients received a cumulative oral dose of ¹³¹I exceeding 150 mCi (5.55 GBq) over approximately 53 months.

The results showed the following:

-In DTC/-T2DM patients, high-cumulative ¹³¹I doses promote a pro-inflammatory state that accelerates the development of cardiotoxicity. Monitoring NT-proBNP, ST2/IL-33R, and cTn I in these patients may help identify those at risk of developing cardiac complications.

– In patients with DTC/+T2DM, high-cumulative ¹³¹I doses lead to the release of NT-proANP (r = 0.63), which signals that the atria are under significant stress.

-In patients with DTC/+T2DM, metformin suppresses inflammation, leading to a dose-dependent reduction in cTn I (r = -0.59). Monitoring cTn I and NT-proANP, and considering the use of metformin as part of the therapeutic strategy, could help manage cardiotoxicity in T2DM patients undergoing ¹³¹I therapy.

NT-proANP – a Biomarker for Cardiac Risk

Biomedica NT-proANP (cat. no. BI-20892) and NT-proBNP (cat. no. SK-1204) ELISA Assay Kits

• Trusted – widely cited in over 300 publications
• Quality – fully validated assays following international quality guidelines
• Convenient – kits include pre-diluted calibrators and 2 controls

 

Related publications

Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial. Schmalstieg-Bahr K, Gladstone DJ, Hummers E, Suerbaum J, Healey JS, Zapf A, Köster D, Werhahn SM, Wachter R. Eur J Gen Pract. 2024 Dec;30(1):2327367. doi: 10.1080/13814788.2024.2327367. Epub 2024 Mar 18. PMID: 38497412; PMCID: PMC10949835.

Evaluation of left atrial volume and functions by 3D echocardiography in patients with prediabetes and investigation of its correlation with NT-pro ANP levels. Eyyupkoca, Hidayet, Özyalın, Bayramoğlu, Altıntaş, Yağmur, Northwestern Med J (2022) 2 (1), 40-50 DOI: 10.54307/nwmj.2022.33043

Relationship of Natriuretic Peptides with Left Atrial Structure and Function within 1 Month after Electrical Cardioversion in Patients with Persistent Atrial Fibrillation. Karaliute R, Jureviciute J, Jurgaityte J, Stanaitiene G, Mizariene V, Kazakevicius T, Urboniene D, Kavoliuniene A. Biomed Res Int. 2019 Mar 17;2019:7636195. doi: 10.1155/2019/7636195. PMID: 31008112; PMCID: PMC6441525.